Back to News
Market Impact: 0.25
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
In a subgroup with baseline 6MWD below the trial median (333m), TNX-103 improved distance by 26.3m versus placebo, with p = 0.0112. The statistically significant benefit in this at-risk segment supports clinical efficacy, though it is subgroup-specific rather than full-trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Apple releases HomeView smart home hub with screen as showcase for Siri AI
- Microsoft Eyes First Record in Nearly a Year as AI Rally Builds
- Why did investors react so negatively to Schneider-PTC deal? M&A expert weighs in
- Bumble agrees to a $1.3B acquisition deal as online dating faces a reset
- Vans is gaining ground with teens. Its owner's stock stands to gain too, Piper Sandler says
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund